prnb-10q_20200331.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2020

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________ 

Commission File Number: 001-38653

 

Principia Biopharma Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware

26-3487603

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer
Identification No.)

220 East Grand Avenue

South San Francisco, California

94080

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (650) 416-7700

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

  

Accelerated filer

 

 

 

 

 

Non-accelerated filer

 

 

  

Smaller reporting company

 

 

 

 

 

 

 

 

Emerging growth company

 

 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, Par Value $0.0001 Per Share

PRNB

 

The Nasdaq Global Select Market

As of April 30, 2020, the registrant had 33,040,758 shares of common stock, $0.0001 par value per share, outstanding.

 

 

 


Table of Contents

 

 

 

 

Page

PART I.

FINANCIAL INFORMATION

 

1

Item 1.

Financial Statements (Unaudited)

 

1

 

Condensed Consolidated Balance Sheets

 

1

 

Condensed Consolidated Statements of Operations

 

2

 

Condensed Consolidated Statements of Comprehensive Loss

 

3

 

Condensed Consolidated Statements of Stockholders’ Equity

 

4

 

Condensed Consolidated Statements of Cash Flows

 

5

 

Notes to Unaudited Condensed Consolidated Financial Statements

 

6

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

17

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

 

26

Item 4.

Controls and Procedures

 

26

PART II.

OTHER INFORMATION

 

28

Item 1.

Legal Proceedings

 

28

Item 1A.

Risk Factors

 

28

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

 

68

Item 3.

Defaults Upon Senior Securities

 

68

Item 4.

Mine Safety Disclosures

 

68

Item 5.

Other Information

 

68

Item 6.

Exhibits

 

69

Signatures

 

70

 

 


i


SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Quarterly Report contains forward-looking statements that involve risks, uncertainties and assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The statements contained in this Quarterly Report that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would” and similar expressions or variations intended to identify forward-looking statements. These statements are based on the beliefs and assumptions of our management, which are in turn based on information currently available to management. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section entitled “Risk Factors” included under Part II, Item 1A below. Furthermore, such forward-looking statements speak only as of the date of this report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.

 

ii


PART I—FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

PRINCIPIA BIOPHARMA INC.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands, except share and per share amounts)

 

 

 

March 31, 2020

 

 

December 31, 2019

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

59,427

 

 

$

39,537

 

Short-term marketable securities

 

 

252,042

 

 

 

276,043

 

Prepaid expenses and other current assets

 

 

4,627

 

 

 

4,165

 

Total current assets

 

 

316,096

 

 

 

319,745

 

Property and equipment, net

 

 

9,363

 

 

 

9,687

 

Operating lease right-of-use asset

 

 

6,624

 

 

 

 

Restricted cash

 

 

567

 

 

 

567

 

Long-term marketable securities

 

 

29,645

 

 

 

52,257

 

Other long-term assets

 

 

480

 

 

 

480

 

Total assets

 

$

362,775

 

 

$

382,736

 

Liabilities and stockholders' equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

1,623

 

 

$

1,850

 

Deferred rent, current portion

 

 

 

 

 

1,181

 

Operating lease liability, current portion

 

 

1,829

 

 

 

 

Accrued research and development liabilities

 

 

10,365

 

 

 

5,791

 

Accrued other liabilities

 

 

956

 

 

 

602

 

Accrued compensation

 

 

3,248

 

 

 

6,715

 

Total current liabilities

 

 

18,021

 

 

 

16,139

 

Long-term deferred rent

 

 

 

 

 

7,619

 

Long-term operating lease liability

 

 

13,306

 

 

 

 

Commitments and contingencies (Note 7)

 

 

 

 

 

 

 

 

Stockholders' equity

 

 

 

 

 

 

 

 

Common stock, $0.0001 par value, 500,000,000 shares authorized

    at March 31, 2020 and December 31, 2019; 33,026,825 and

    32,950,836 shares issued and outstanding at March 31, 2020

    and December 31, 2019, respectively

 

 

3

 

 

 

3

 

Additional paid-in capital

 

 

549,622

 

 

 

544,709

 

Accumulated other comprehensive income

 

 

65

 

 

 

9

 

Accumulated deficit

 

 

(218,242

)

 

 

(185,743

)

Total stockholders' equity

 

 

331,448

 

 

 

358,978

 

Total liabilities and stockholders’ equity

 

$

362,775

 

 

$

382,736

 

 

See accompanying notes.

1


PRINCIPIA BIOPHARMA INC.

Condensed Consolidated Statements of Operations

(Unaudited)

(In thousands, except share and per share amounts)

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2020

 

 

2019

 

Revenue

 

$

 

 

$

5,160

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

 

 

26,742

 

 

 

15,523

 

General and administrative

 

 

7,369

 

 

 

4,508

 

Total operating expenses

 

 

34,111

 

 

 

20,031

 

Loss from operations

 

 

(34,111

)

 

 

(14,871

)

Other income, net

 

 

 

 

 

1

 

Interest income

 

 

1,612

 

 

 

1,183

 

Net loss

 

$

(32,499

)

 

$

(13,687

)

Net loss per share, basic and diluted

 

$

(0.99

)

 

$

(0.57

)

Weighted-average shares used to calculate net loss

   per share, basic and diluted

 

 

32,993,753

 

 

 

23,866,066

 

 

See accompanying notes.

2


PRINCIPIA BIOPHARMA INC.

Condensed Consolidated Statements of Comprehensive Loss

(Unaudited)

(In thousands)

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2020

 

 

2019

 

Net loss

 

$

(32,499

)

 

$

(13,687

)

Other comprehensive income:

 

 

 

 

 

 

 

 

Net unrealized gain on available-for-sale securities

 

 

56

 

 

 

149

 

Comprehensive loss

 

$

(32,443

)

 

$

(13,538

)

 

See accompanying notes.


3


PRINCIPIA BIOPHARMA INC.

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited)

(In thousands, except share amounts)

 

 

 

 

Common Stock

 

 

Additional

 

 

Accumulated

Other

 

 

 

 

 

 

Total

 

 

 

 

Number of

Shares

 

 

$0.0001

Par Value

 

 

Paid-In

Capital

 

 

Comprehensive

Income

 

 

Accumulated

Deficit

 

 

Stockholders'

Equity

 

Balance at December 31, 2019

 

 

 

32,950,836

 

 

$

3

 

 

$

544,709

 

 

$

9

 

 

$

(185,743

)

 

$

358,978

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

4,389

 

 

 

 

 

 

 

 

 

4,389

 

Exercise of stock options and vesting of early exercise shares

 

 

 

75,989

 

 

 

 

 

 

524

 

 

 

 

 

 

 

 

 

524

 

Unrealized gain on available-for-sale securities

 

 

 

 

 

 

 

 

 

 

 

 

56

 

 

 

 

 

 

56

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(32,499

)

 

 

(32,499

)

Balance at March 31, 2020

 

 

 

33,026,825

 

 

$

3

 

 

$

549,622

 

 

$

65

 

 

$

(218,242

)

 

$

331,448

 

 

 

 

 

Common Stock

 

 

Additional

 

 

Accumulated

Other

 

 

 

 

 

 

Total

 

 

 

 

Number of

Shares

 

 

$0.0001

Par Value

 

 

Paid-In

Capital

 

 

Comprehensive

Income (Loss)

 

 

Accumulated

Deficit

 

 

Stockholders'

Equity

 

Balance at December 31, 2018

 

 

 

23,865,451

 

 

$

2

 

 

$

302,393

 

 

$

(128

)

 

$

(132,407

)

 

$

169,860

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

2,205

 

 

 

 

 

 

 

 

 

2,205

 

Exercise of stock options and vesting of early exercise shares

 

 

 

1,230

 

 

 

 

 

 

7

 

 

 

 

 

 

 

 

 

7

 

Unrealized gain on available-for-sale securities

 

 

 

 

 

 

 

 

 

 

 

 

149

 

 

 

 

 

 

149

 

Cumulative-effect adjustment from adoption of ASC 606 accounting standard on revenue recognition

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

456

 

 

 

456

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(13,687

)

 

 

(13,687

)

Balance at March 31, 2019

 

 

 

23,866,681

 

 

$

2

 

 

$

304,605

 

 

$

21

 

 

$

(145,638

)

 

$

158,990

 

 

See accompanying notes.

 

4


PRINCIPIA BIOPHARMA INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

 

 

Three Months Ended March 31,

 

 

 

2020

 

 

2019

 

Operating activities:

 

 

 

 

 

 

 

 

Net loss

 

$

(32,499

)

 

$

(13,687

)

Adjustments to reconcile net loss to net cash used in

   operating activities:

 

 

 

 

 

 

 

 

Amortization of discount on marketable securities

 

 

(347

)

 

 

(526

)

Depreciation

 

 

502

 

 

 

346

 

Stock-based compensation

 

 

4,389

 

 

 

2,205

 

Deferred rent

 

 

 

 

 

472

 

Non-cash lease expense

 

 

131

 

 

 

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Prepaid expenses and other assets

 

 

(462

)

 

 

471

 

Deferred revenue

 

 

 

 

 

(5,160

)

Accounts payable

 

 

(227

)

 

 

(35

)

Accrued liabilities

 

 

1,461

 

 

 

(492

)

Lease liability

 

 

(420

)

 

 

 

Net cash used in operating activities

 

 

(27,472

)

 

 

(16,406

)

Investing activities:

 

 

 

 

 

 

 

 

Purchases of property and equipment

 

 

(178

)

 

 

(1,376

)

Maturities of marketable securities

 

 

84,761

 

 

 

34,410

 

Purchases of marketable securities

 

 

(37,745

)

 

 

(36,536

)

Net cash provided by (used in) investing activities

 

 

46,838

 

 

 

(3,502

)

Financing activities:

 

 

 

 

 

 

 

 

Proceeds from issuances of common stock upon exercise of options and participation in employee stock purchase plan

 

 

524

 

 

 

7

 

Net cash provided by financing activities

 

 

524

 

 

 

7

 

Net increase (decrease) in cash, cash equivalents and restricted cash

 

 

19,890

 

 

 

(19,901

)

Cash, cash equivalents and restricted cash at beginning

   of period

 

 

40,104

 

 

 

35,138

 

Cash, cash equivalents and restricted cash, at end of period

 

$

59,994

 

 

$

15,237

 

Supplemental disclosures of cash flow information

 

 

 

 

 

 

 

 

Non cash tenant improvement allowance used for leasehold improvements

 

$

 

 

$

8,324

 

Purchases of property and equipment accrued but not yet paid

 

$

 

 

$

293

 

 

See accompanying notes.

 

5


 

PRINCIPIA BIOPHARMA INC.

Notes to Unaudited Condensed Consolidated Financial Statements

1. Organization

Description of Business

We, Principia Biopharma Inc. (“Principia”), are a late-stage biopharmaceutical company dedicated to bringing transformative therapies to patients with significant unmet medical needs in immune-mediated diseases. We were incorporated on October 6, 2008, began operations in February 2011, and are headquartered in South San Francisco, California.

2. Significant Accounting Policies

Basis of Presentation

The accompanying interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and include the accounts of Principia and our wholly-owned Australian subsidiary. All intercompany accounts, transactions and balances have been eliminated. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”).

These interim condensed consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments of a normal and recurring nature that are necessary for the fair presentation of our financial position and results of operations for the periods presented. The condensed consolidated balance sheets as of December 31, 2019 included herein were derived from audited consolidated financial statements as of that date. This quarterly report should be read in conjunction with our audited consolidated financial statements included in our Annual Report on Form 10-K filed with the SEC on March 10, 2020 (“2019 Annual Report”).

Use of Estimates

The preparation of our financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as well as related disclosure of contingent assets and liabilities. Significant estimates include amounts to determine the fair value of common stock-based awards, warrants, and other issuances, embedded derivatives, accruals for research and development costs and uncertain tax positions, and the estimated periods of performance used in the determination of collaboration revenues. We base our estimates on historical experience and on various other market specific and relevant assumptions that our management believes to be reasonable under the circumstances. Actual results could differ materially from our estimates.

Concentration of Credit Risk and Other Risks and Uncertainties

Financial instruments that potentially subject us to a significant concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. Our cash and cash equivalents are maintained with a limited number of financial institutions in the United States. Cash amounts on deposit have exceeded and will continue to exceed federally insured limits. We have not experienced any losses on our cash deposits. Additionally, we have established guidelines regarding the diversification of our investments in approved instruments, their credit quality ratings and maturities. The guidelines are designed to preserve principal balances and provide liquidity. Cash, cash equivalents and marketable securities totaled $341.1 million and $367.8 million at March 31, 2020 and December 31, 2019, respectively.

We are subject to a number of risks similar to other biopharmaceutical companies with development and pre-commercial operations, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future preclinical studies or clinical trials or delays in the progress of such trials, our reliance on third parties or partners to conduct our clinical trials, the need to obtain regulatory and marketing approvals for our drug candidates or to rely on partners to do so, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of our drug candidates, delays or problems in the supply of our drug candidates, loss of single source suppliers or failure to comply with manufacturing regulations, identifying other drug candidates, product development and the inherent uncertainty of clinical success, our right to develop and commercialize our drug candidates pursuant to the terms and conditions of the licenses granted to us, protection of proprietary technology, the ability to make or collect milestone, royalty or other payments due, or due to us, under any license or collaboration agreements, and the need to secure and maintain adequate manufacturing arrangements with third parties. If we do not successfully commercialize or partner any of our drug candidates, we will be unable to generate product revenue or achieve profitability.

6


 

Cash and Cash Equivalents

We consider all highly liquid financial instruments with original maturities of 90 days or less at the date of purchase to be cash equivalents. Cash equivalents are stated at fair value.

Marketable Securities

We carry marketable securities consisting primarily of money market funds, U.S. Treasury securities and obligations of government-sponsored enterprises and corporate bonds and commercial paper. Marketable securities with maturities greater than 90 days at the time of purchase and that mature less than one year from the consolidated balance sheet date are classified as short-term. Marketable securities with a maturity date greater than one year at each balance sheet date are classified as long-term. All of our marketable securities are considered available-for-sale and carried at estimated fair values on the condensed consolidated balance sheets. Unrealized gains or losses, when such losses are not deemed to be credit-related, are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders’ equity on the condensed consolidated balance sheets. Credit-related losses, if any, are recognized in earnings and limited to the difference between the security's fair value and its amortized cost basis. Realized gains and losses from sales of marketable securities are included in other income (expense), net. The cost of securities sold is based on the specific-identification method. Interest earned on marketable securities is included in interest income. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts and such amortization and accretion are included as a component of interest income.

Restricted Cash

As of March 31, 2020 and December 31, 2019, we had $0.6 million in long-term restricted cash for a lease security deposit. This amount is separated from cash and cash equivalents on the condensed consolidated balance sheets.

Segments

We have one operating segment. Our chief operating decision maker, our President and Chief Executive Officer, manages our operations on a consolidated basis in assessing performance and allocating resources.

Leases

We enter into operating lease agreements for our laboratory and office facilities. Effective January 1, 2020, we adopted Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), or ASC 842, using a modified retrospective approach. Under this approach, we recorded an operating lease right-of-use (“ROU”) asset and lease liability of approximately $6.8 million and $15.6 million, respectively, and eliminated the previously recorded deferred rent of $8.8 million in our condensed consolidated balance sheet as of the adoption date. There was no impact to accumulated deficit upon adoption.

 

We determine whether an arrangement is or contains a lease at inception. For operating leases, we recognize a ROU asset and operating lease liability in our condensed consolidated balance sheets. ROU assets represent our right to use an underlying asset during the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. We recognize ROU assets and lease liabilities at lease commencement based on the present value of lease payments due over the lease term, and adjust ROU assets for any lease prepayments made or lease incentives received. In determining the present value of lease payments, we use the rate implicit in the lease, if known, or we use an estimated incremental borrowing rate based on the information available at the lease commencement date.

 

We recognize lease expense on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet. We do not assume renewals in our determination of the lease term unless the renewals are deemed to be reasonably assured at lease inception. 

Revenue Recognition

Effective January 1, 2019, we adopted ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), or ASC 606, using the modified retrospective approach. Under this approach, we recorded a cumulative adjustment to decrease accumulated deficit and deferred revenue by $0.4 million as of the adoption date. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and

7


 

(v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods and services we transfer to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract, determine those that are performance obligations and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

We have entered into licensing and collaboration agreements that are within the scope of ASC 606. In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under such licensing and collaboration agreements, we perform the five-step model under ASC 606. As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. 

Licenses of Intellectual Property:  If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promised goods or services, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.

Milestone Payments:  At the inception of each arrangement that includes development, regulatory or commercial milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant reversal of cumulative revenue would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or that of our licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received or the underlying activity has been completed. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenue in the period of adjustment. 

Royalties:  For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue resulting from any of our licensing arrangements.

 

During the three months ended March 31, 2020, we did not recognize any revenue from performance obligations satisfied in previous periods.

Comprehensive Income (Loss)

Comprehensive income (loss) is defined as the change in stockholders’ equity (deficit) of a business enterprise during a period, resulting from transactions from non-owner sources, and consists primarily of unrealized gains or losses related to our available-for-sale marketable securities, which are carried at estimated fair values on the consolidated balance sheets.

Net Income (Loss) per Share

Basic net income (loss) per share is calculated by dividing our net income (loss) by the weighted-average number of shares of common stock outstanding for the period.

Diluted net income (loss) per share includes the effect of potentially dilutive securities, which include outstanding warrants and stock options if the effect of their inclusion would be dilutive. In periods of net loss, diluted net loss per share is the same as basic net loss per share as the inclusion of potentially dilutive securities in the calculation would be anti-dilutive.

Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on our condensed consolidated financial statements upon

8


 

adoption. Under the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), we meet the definition of an emerging growth company, and have elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act.

Recently Adopted Accounting Standards or Updates

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The ASU requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. The ASU also requires new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements, permitting another transition method for ASC 842, which allows companies to reflect any transition impact as a cumulative-effect adjustment to its opening retained earnings at the adoption date, without adjusting any comparative information presented in the financial statements. We adopted ASC 842 on January 1, 2020 using a modified retrospective approach and elected the transition method described above. As a result, our condensed consolidated financial statements for the period beginning January 1, 2020 are presented under the new leases standard, while prior comparative periods are reported consistent with prior accounting standards. We elected the package of practical expedients upon transition to carryforward our prior conclusions regarding contracts containing leases and lease classifications. We also elected, as ongoing accounting policies, not to apply the requirements of ASC 842 to short-term leases (generally those with initial terms of 12 months or less) and to combine the accounting for lease and non-lease components. Upon adoption, we recorded an operating lease ROU asset and lease liability related to our corporate headquarters lease and eliminated the previously recorded deferred rent in our condensed consolidated balance sheet. There was no impact to accumulated deficit upon adoption. See Note 7, Commitments and Contingencies, for additional information.

In June 2016, the FASB issued ASU No. 2016-13, Financial InstrumentsCredit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The updated accounting guidance requires changes to the recognition of credit losses on financial instruments not accounted for at fair value through net income. Specifically, the ASU requires companies to recognize an allowance for credit losses on available-for-sale debt securities that are impaired as a result of credit-related factors and replaces the prior other-than-temporary impairment model. We adopted this ASU effective January 1, 2020 and the adoption did not have a material impact on our condensed consolidated financial statements and related disclosures.

In June 2018, the FASB issued ASU No. 2018-07, Compensation–Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. This ASU simplifies the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. We adopted this ASU effective January 1, 2020 and the adoption did not have a material impact on our condensed consolidated financial statements and related disclosures. Our share-based payments related to nonemployees is insignificant.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework–Changes to the Disclosure Requirements for Fair Value Measurement. This ASU eliminates, modifies and adds disclosure requirements for fair value measurements. We adopted this ASU effective January 1, 2020 and the adoption did not have a material impact on our condensed consolidated financial statements and related disclosures.

3. Fair Value Measurements

Financial assets and liabilities are recorded at fair value. We determine fair value using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:

Level 1 inputs include quoted prices in active markets for identical assets or liabilities.

Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; and other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability.

Level 3 inputs include unobservable inputs that are supported by little or no market activity and are significant to the fair value of the underlying asset or liability. Such inputs reflect our best estimate of what market participants would use in pricing the asset or liability at the reporting date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires our management to make judgments and consider factors specific to the asset or liability.

9


 

Assets and liabilities measured at fair value on a recurring basis as of March 31, 2020 and December 31, 2019 were as follows (in thousands):

 

 

 

March 31, 2020

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

54,841

 

 

$

 

 

$

 

 

$

54,841

 

Short-term marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate commercial paper

 

 

 

 

 

93,347

 

 

 

 

 

 

93,347

 

Corporate debt securities

 

 

 

 

 

142,640

 

 

 

 

 

 

142,640

 

Government‑sponsored enterprise securities

 

 

 

 

 

16,055

 

 

 

 

 

 

16,055

 

Long-term marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

 

 

 

 

8,534

 

 

 

 

 

 

8,534

 

Government‑sponsored enterprise securities

 

 

 

 

 

21,111

 

 

 

 

 

 

21,111

 

Total

 

$

54,841

 

 

$

281,687

 

 

$

 

 

$

336,528

 

 

 

 

December 31, 2019

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

17,664

 

 

$

 

 

$

 

 

$

17,664

 

Corporate commercial paper

 

 

 

 

 

6,983

 

 

 

 

 

 

6,983

 

Corporate debt securities

 

 

 

 

 

10,204

 

 

 

 

 

 

10,204

 

Short-term marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate commercial paper

 

 

 

 

 

95,088

 

 

 

 

 

 

95,088

 

Corporate debt securities

 

 

 

 

 

154,690

 

 

 

 

 

 

154,690

 

Government‑sponsored enterprise securities

 

 

 

 

 

26,265

 

 

 

 

 

 

26,265

 

Long-term marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

 

 

 

 

14,202

 

 

 

 

 

 

14,202

 

Government‑sponsored enterprise securities

 

 

 

 

 

38,055

 

 

 

 

 

 

38,055

 

Total

 

$

17,664

 

 

$

345,487

 

 

$

 

 

$

363,151

 

The carrying amounts of accounts payable and accrued liabilities approximate their fair values due to their short-term maturities. Our Level 2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly. There were no transfers of assets or liabilities between the fair value measurement levels during the three months ended March 31, 2020 and 2019.

10


 

4. Cash Equivalents and Marketable Securities

Cash equivalents and marketable securities consisted of the following as of March 31, 2020 and December 31, 2019 (in thousands):

 

 

 

March 31, 2020

 

 

 

Amortized

Cost

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Fair Value

 

Cash equivalents

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

54,841

 

 

$

 

 

$

 

 

$

54,841

 

Total cash equivalents

 

 

54,841

 

 

 

 

 

 

 

 

 

54,841

 

Short-term marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate commercial paper

 

 

93,091

 

 

 

256

 

 

 

 

 

 

93,347

 

Corporate debt securities

 

 

142,848

 

 

 

99

 

 

 

(307

)

 

 

142,640

 

Government‑sponsored enterprise securities

 

 

15,994

 

 

 

61

 

 

 

 

 

 

16,055

 

Total short-term marketable securities

 

 

251,933

 

 

 

416

 

 

 

(307

)

 

 

252,042

 

Long-term marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

 

8,563

 

 

 

 

 

 

(29

)

 

 

8,534

 

Government‑sponsored enterprise securities

 

 

21,037

 

 

 

74

 

 

 

 

 

 

21,111

 

Total long-term marketable securities

 

 

29,600

 

 

 

74

 

 

 

(29

)

 

 

29,645

 

Total

 

$

336,374

 

 

$

490

 

 

$

(336

)

 

$

336,528

 

 

 

 

December 31, 2019

 

 

 

Amortized

Cost

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Fair Value

 

Cash equivalents

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

17,664

 

 

$

 

 

$

 

 

$

17,664

 

Corporate commercial paper

 

 

6,982

 

 

 

1

 

 

 

 

 

 

6,983

 

Corporate debt securities

 

 

10,205

 

 

 

 

 

 

(1

)

 

 

10,204

 

Total cash equivalents

 

 

34,851

 

 

 

1

 

 

 

(1

)

 

 

34,851

 

Short-term marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate commercial paper

 

 

95,061

 

 

 

36

 

 

 

(9

)

 

 

95,088

 

Corporate debt securities

 

 

154,678

 

 

 

54

 

 

 

(42

)

 

 

154,690

 

Government‑sponsored enterprise securities

 

 

26,231

 

 

 

34

 

 

 

 

 

 

26,265

 

Total short-term marketable securities

 

 

275,970

 

 

 

124

 

 

 

(51

)

 

 

276,043

 

Long-term marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

 

14,194

 

 

 

8

 

 

 

 

 

 

14,202

 

Government‑sponsored enterprise securities

 

 

38,037

 

 

 

18

 

 

 

 

 

 

38,055

 

Total long-term marketable securities

 

 

52,231

 

 

 

26

 

 

 

 

 

 

52,257

 

Total

 

$

363,052

 

 

$

151

 

 

$

(52

)

 

$

363,151

 

All our marketable securities are considered available-for-sale. There were no sales of available-for-sale marketable securities in any of the periods presented. The aggregate fair value of marketable securities that were in unrealized loss positions was approximately $107.4 million as of March 31, 2020 and included 16 investment positions with aggregate unrealized losses of approximately $0.3 million. Unrealized losses on an individual security basis was immaterial. We had aggregate net unrealized gains of approximately $0.2 million and $0.1 million at March 31, 2020 and December 31, 2019, respectively, with respect to our entire marketable securities portfolio.

As of March 31, 2020, we did not have the intent, and management had not made any decisions, to sell our investments that were in an unrealized loss position and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost basis. We anticipate that we will recover the entire amortized cost basis of such securities and have determined that a credit loss did not exist as of March 31, 2020. At March 31, 2020, the remaining contractual maturities of long-term marketable securities were less than two years. In April 2020, we decided to sell certain of our short-term and long-term marketable securities and received approximately $101.9 million in gross proceeds, realizing a net gain of $0.2 million.

11


 

5. Balance Sheet Components

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the amounts shown in the condensed consolidated statements of cash flows (in thousands):

 

 

 

March 31, 2020

 

 

December 31, 2019

 

 

March 31, 2019

 

 

December 31, 2018

 

Cash and cash equivalents

 

$

59,427

 

 

$

39,537

 

 

$

14,670

 

 

$

34,489

 

Restricted cash, current

 

 

 

 

 

 

 

 

 

 

 

82

 

Restricted cash, non-current

 

 

567

 

 

 

567

 

 

 

567

 

 

 

567

 

Total

 

$

59,994

 

 

$

40,104

 

 

$

15,237

 

 

$

35,138

 

Property and equipment as of March 31, 2020 and December 31, 2019 consisted of the following (in thousands):

 

 

 

March 31, 2020

 

 

December 31, 2019

 

Laboratory equipment

 

$

2,174

 

 

$

2,007

 

Computer equipment

 

 

289

 

 

 

289

 

Furniture and fixtures

 

 

1,560

 

 

 

1,549

 

Leasehold improvements

 

 

8,324

 

 

 

8,324

 

 

 

 

12,347

 

 

 

12,169

 

Less accumulated depreciation and amortization

 

 

(2,984

)

 

 

(2,482

)

Total

 

$

9,363

 

 

$

9,687

 

 

Prepaid expenses and other current assets as of March 31, 2020 and December 31, 2019 consisted of the following (in thousands):

 

 

 

March 31, 2020

 

 

December 31, 2019

 

Other accounts receivable

 

$

1,515

 

 

$

1,272